摘要
目的:抗癌扶正协定方是医院的协定方,自1977年开始使用以来,在肺癌的辅助治疗方面取得了理想的效果。研究旨在研究此方对荷瘤小鼠外周血免疫细胞的影响。方法:通过荷瘤小鼠的模型建立、分组、给药以及数学统计分析,得出抗癌扶正协定方与荷瘤小鼠外周血免疫细胞的关系。结果:抗癌扶正协定方在喂饲后,在小鼠的血细胞计数、淋巴细胞及脾脏的重量上,与对照组相比,无显著性差异。但在与顺铂联合使用后,联合组的白细胞计数为(2.62±1.20)×109/L,血小板计数为(90.33±90.11)×109/L,CD4的含量为(31.83±3.54)%,脾脏的重量为(0.045±0.016)g,与荷瘤对照组相比有显著性差异。结论:抗癌扶正协定方对荷瘤C57/BL6J小鼠外周血免疫细胞的影响有限,但在与化疗药物联合作用时,可有效的降低化疗药物对机体的损害。
Objective : Kang' ai Fuzheng Xieding Formula (KAFZ) has been used for treating lung cancer in our hospi-tal from 1977. The aim of the study is to investigate the effects of this prescription on the immunocytes. Method: Thecounts of blood cell,lymphocyte and the weight of spleen were measured in the tumor - transplanted C57/BL6J mice. Re-suit:Compared with the control group, oral KAFZ alone showed no significant effect on those above motioned parameters.However, the combination of KAFZ and showed significant differences with control group,in which the WBC was (2.62 ±1.20) 109/L and PC was (90.33 ± 90.11 ) 109/L and the content of CD4 was (31.83 ± 3.54)% and the weight ofspleen was (0. 045 ± 0.016) g. Conclusion:Oral KAFZ alone has no significant effects on immunocytes but it can reversethe immunosuppressive effect by chemotherapy drug. Koy words: Karigti Fuzheng' Xieding Formula ; peripheral blood immunocytes
出处
《中华中医药学刊》
CAS
北大核心
2015年第1期113-115,共3页
Chinese Archives of Traditional Chinese Medicine
基金
浙江省中医药科技计划项目(2008CA037)
关键词
抗癌扶正协定方
免疫细胞
Kangai Fuzheng' Xieding Formula
peripheral blood immunocytes